Place · Level 3 · Supplement
α-Lipoic acid (ALA)
线粒体辅基不是营养素 · 糖尿病周围神经病变 IV 用药真证据 · 减脂营销 -0.65 kg 真相 · R-ALA 商业溢价拆穿
Last updated
Story path
Chapter 1
Dual-soluble
Dual-soluble
α-lipoic acid (ALA / thioctic acid) is an 8-carbon fatty acid containing a disulfide (-S-S-) ring, first isolated in 1951 by Reed's lab.
What's special about the chemical structure:
8-carbon fatty acid backbone → lipid-solubleDisulfide bond + carboxyl group → water-solubleDual water/lipid solubility, quite rare among vitamins + antioxidantsVit C is water-only, vit E / A lipid-only, GSH water-only — most antioxidants work in one phase onlyALA can enter cytosol, membranes, mitochondria, and nucleus simultaneously
Two stereoisomers (chirality):
R-ALA (dextrorotatory): the naturally occurring form, also what the body synthesizes and usesS-ALA (levorotatory): a synthetic byproduct, weak biological activityCommercial ALA is usually racemic (50% R + 50% S) — low industrial-synthesis costR-ALA-only products advertise 'natural form', but oral R-ALA has poor stability (polymerizes); only salt forms like R-ALA-Na are actually stable
Endogenous synthesis:
ALA is synthesized inside mitochondria from octanoic acid + sulfur supplyNot an essential nutrient (unlike vitamins, which must come from food)But synthesis may decline under aging / pathology, so supplementation has some theoretical rationale
Food content:
Red meat (organ): 5–30 µg/100 gSpinach / broccoli: ~5 µg/100 gYeast / tomato: traceFood content is extremely low — reaching supplemental doses (300–600 mg) from food is impossible
Key fact: 'ALA is an essential nutrient' is supplement-marketing misdirection. It's not a vitamin and not a 'deficiency-causes-disease' molecule — it's an endogenous metabolic cofactor + an optional therapeutic drug (IV in diabetic neuropathy).
What's special about the chemical structure:
8-carbon fatty acid backbone → lipid-solubleDisulfide bond + carboxyl group → water-solubleDual water/lipid solubility, quite rare among vitamins + antioxidantsVit C is water-only, vit E / A lipid-only, GSH water-only — most antioxidants work in one phase onlyALA can enter cytosol, membranes, mitochondria, and nucleus simultaneously
Two stereoisomers (chirality):
R-ALA (dextrorotatory): the naturally occurring form, also what the body synthesizes and usesS-ALA (levorotatory): a synthetic byproduct, weak biological activityCommercial ALA is usually racemic (50% R + 50% S) — low industrial-synthesis costR-ALA-only products advertise 'natural form', but oral R-ALA has poor stability (polymerizes); only salt forms like R-ALA-Na are actually stable
Endogenous synthesis:
ALA is synthesized inside mitochondria from octanoic acid + sulfur supplyNot an essential nutrient (unlike vitamins, which must come from food)But synthesis may decline under aging / pathology, so supplementation has some theoretical rationale
Food content:
Red meat (organ): 5–30 µg/100 gSpinach / broccoli: ~5 µg/100 gYeast / tomato: traceFood content is extremely low — reaching supplemental doses (300–600 mg) from food is impossible
Key fact: 'ALA is an essential nutrient' is supplement-marketing misdirection. It's not a vitamin and not a 'deficiency-causes-disease' molecule — it's an endogenous metabolic cofactor + an optional therapeutic drug (IV in diabetic neuropathy).
分子档案 · 结构 / 手性 / 合成 / 食物里有多少
第一屏讲的是它在身体里干什么。这一页是它的分子档案: 结构长什么样、为什么水油两边都去得了、两种镜像分子差在哪、身体怎么造它, 以及食物里到底有多少。α-硫辛酸 (alpha-lipoic acid, ALA / thioctic acid) 是一个 8 碳脂肪酸, 含有一个二硫键 (-S-S-) 环, 1951 年由 Reed 实验室首次分离。
化学结构特别在哪里:
8 碳脂肪酸骨架 → 脂溶性二硫键 + 羧基 → 水溶性同时水脂双溶, 在维生素 + 抗氧化剂里相当罕见vit C 只水溶, vit E / A 只脂溶, GSH 只水溶, 大多数抗氧化剂只能在水相或脂相工作ALA 可以同时进入细胞液、膜、线粒体、细胞核
两种立体异构 (chirality):
R-ALA (右旋): 天然存在的形式, 也是身体合成 + 利用的形式S-ALA (左旋): 合成副产物, 生物活性弱商业 ALA 通常是 racemic (50% R + 50% S), 工业合成成本低R-ALA 专售标榜天然形式, 但口服 R-ALA 稳定性差 (聚合), 实际 R-ALA-Na 等盐形式才稳定
身体合成:
线粒体里 ALA 是内源合成的, 从辛酸 (octanoic acid) + 硫供给不是必需营养素 (不像维生素必须从食物获取)但衰老、病理状态下合成可能下降, 部分补充有理论意义
食物含量:
红肉 (内脏): 5-30 µg/100g菠菜、西兰花: 约 5 µg/100g酵母、番茄: 微量食物含量极少, 想达到补剂剂量 (300-600 mg) 不可能靠食物
关键事实: ALA 是必需营养素 是补剂营销误导。它不是维生素, 也不是缺乏会生病的分子, 而是内源代谢辅基 + 可选治疗药 (糖尿病神经病变 IV 用药)。
R-ALA premium debunked
'R-ALA is the natural form, S-ALA is useless, you must buy pure R-ALA' — the supplement-marketing 'chirality premium' line. Let's go through the evidence point by point.First, R-ALA really is the natural + biologically active form:
Mitochondrial ALA is the R formPDH / KGDH cofactor is the R formS-ALA basically cannot enter the active sites of mitochondrial enzymes
Second, but after oral dosing the two forms diverge:
Oral R-ALA is unstable in gastric acid, polymerizes easily and partially degradesOral S-ALA has better chemical stability but weak biological activityRacemic ALA (50% R + 50% S) is industrially synthesized, with moderate stabilityR-ALA-Na (sodium salt) / R-LA stable forms solve the stability problem but cost 5–10× racemic
Third, PK studies (Carlson 2007 *Altern Med Rev*):
Racemic 300 mg → plasma R-ALA peak 4–5 µM, S-ALA peak 6–8 µMR-ALA-Na 100 mg → plasma R-ALA peak 8–10 µMEfficiency difference: R-ALA-Na is 2–3× more efficient per mg, but whether clinical endpoint improvement matches that gap is weakly supported
Fourth, the ALADIN series RCTs used racemic:
All A-level evidence (diabetic neuropathy) used racemic ALA, not R-ALAR-ALA-only clinical evidence is sparse, mostly PK + small metabolic-marker studies'R-ALA is clinically stronger' is not an evidence-based conclusion — it's a marketing extrapolation
In practice:
If you're certain you want ALA + budget tight: racemic 300–600 mg, $10–20/month, fully reasonableIf you're willing to pay the premium + want theoretical optimum: R-ALA-Na 100–300 mg, $40–80/month'Only buy R-ALA, never racemic' marketing isn't science — the A-level ALADIN evidence used racemic
Bottom line: the chirality premium is a mix of real commercial + PK data + heavy marketing extrapolation. The rational supplementation is to follow the ALADIN protocol with racemic; if you self-experiment with R-ALA-Na, recognize you're paying for theoretical advantage, not RCT evidence.
Chapter 2
Mitochondrial cofactor
Mitochondrial cofactor
ALA's 'day job' in the body is not antioxidant — it's mitochondrial enzyme cofactor. This is the fact most often skipped in marketing.
Key roles:
Pyruvate dehydrogenase (PDH): ALA is covalently bound to the E2 subunit, the key cofactor for pyruvate → acetyl-CoA (TPP/B1 is also a cofactor on the same enzyme; see the thiamin/tpp L4)α-ketoglutarate dehydrogenase (KGDH): key step in the TCA cycleBranched-chain α-keto acid dehydrogenase (BCKD): leucine / isoleucine / valine metabolismGlycine cleavage system: Gly + THF → 5,10-MTHF + CO₂ + NH₃, part of the SHMT pathway mentioned in the Atlas glycine story
So ALA is a central cofactor for glucose metabolism + tricarboxylic acid (Krebs) cycle: The mitochondrial hub cycle that fully oxidizes fuel and harvests electrons for energy. + BCAA + one-carbon metabolism — involving the body's most important metabolic lines.
The 'antioxidant' role is secondary and marketing-amplified:
Dihydrolipoic acid (DHLA) = the reduced form of ALAThe thiol (-SH) on DHLA does clear ROS and chelate heavy metalsBut DHLA is the post-reduction form in vivo; endogenous DHLA concentration is low (because most endogenous ALA is locked into cofactor roles)After oral ALA, the body reduces it to DHLA via GR / thioredoxin reductase, giving a brief antioxidant boostHalf-life ~30 minutes — an acute effect, not sustained
The 'ALA as network-antioxidant hub' framing (Packer 1995):
DHLA can recycle the oxidized forms of vit C, vit E, GSH, CoQ10This is the core of the 'antioxidant network' theory: ALA isn't a point antioxidant but a network hubThe mechanism is real, but clinical endpoint validation is weak (the vit-e/membrane L4 already covered the 'perfect mechanism → failed RCT' lesson; ALA antioxidant RCTs follow the same pattern)
Bottom line:
ALA's primary role is cofactor; with adequate endogenous synthesis no supplementation is neededThe antioxidant function is a side job, briefly present during high-dose supplementation'ALA antioxidant → systemic anti-aging' is another version of the vit E + antioxidant mega-pack marketingIf ALA could really deliver broad-spectrum anti-aging, RCTs would have shown it — but there's no large-trial hard-endpoint RCT evidence for lifespan / CVD / cancerIts real value lies in specific clinical indications, not 'wellness'
Key roles:
Pyruvate dehydrogenase (PDH): ALA is covalently bound to the E2 subunit, the key cofactor for pyruvate → acetyl-CoA (TPP/B1 is also a cofactor on the same enzyme; see the thiamin/tpp L4)α-ketoglutarate dehydrogenase (KGDH): key step in the TCA cycleBranched-chain α-keto acid dehydrogenase (BCKD): leucine / isoleucine / valine metabolismGlycine cleavage system: Gly + THF → 5,10-MTHF + CO₂ + NH₃, part of the SHMT pathway mentioned in the Atlas glycine story
So ALA is a central cofactor for glucose metabolism + tricarboxylic acid (Krebs) cycle: The mitochondrial hub cycle that fully oxidizes fuel and harvests electrons for energy. + BCAA + one-carbon metabolism — involving the body's most important metabolic lines.
The 'antioxidant' role is secondary and marketing-amplified:
Dihydrolipoic acid (DHLA) = the reduced form of ALAThe thiol (-SH) on DHLA does clear ROS and chelate heavy metalsBut DHLA is the post-reduction form in vivo; endogenous DHLA concentration is low (because most endogenous ALA is locked into cofactor roles)After oral ALA, the body reduces it to DHLA via GR / thioredoxin reductase, giving a brief antioxidant boostHalf-life ~30 minutes — an acute effect, not sustained
The 'ALA as network-antioxidant hub' framing (Packer 1995):
DHLA can recycle the oxidized forms of vit C, vit E, GSH, CoQ10This is the core of the 'antioxidant network' theory: ALA isn't a point antioxidant but a network hubThe mechanism is real, but clinical endpoint validation is weak (the vit-e/membrane L4 already covered the 'perfect mechanism → failed RCT' lesson; ALA antioxidant RCTs follow the same pattern)
Bottom line:
ALA's primary role is cofactor; with adequate endogenous synthesis no supplementation is neededThe antioxidant function is a side job, briefly present during high-dose supplementation'ALA antioxidant → systemic anti-aging' is another version of the vit E + antioxidant mega-pack marketingIf ALA could really deliver broad-spectrum anti-aging, RCTs would have shown it — but there's no large-trial hard-endpoint RCT evidence for lifespan / CVD / cancerIts real value lies in specific clinical indications, not 'wellness'
抗氧化网络假说 · 机制漂亮不等于 RCT 能赢
第一屏说抗氧化只是 ALA 的副业。这一页把那份副业最常被引用的理论版本摊开, 顺便看它为什么在临床上一直兑现不了。还有一个常被引用的说法 (Packer 1995): ALA 的还原形式能帮着回收维 C、维 E、谷胱甘肽、CoQ10 这些抗氧化剂用过的状态, 所以它不只是单点抗氧化, 更像抗氧化网络里的一个中枢。这套理论机制上讲得通, 但临床终点验证一直很弱——机制漂亮不等于 RCT 能赢, 维 E 抗氧化那条线就是前车之鉴。
顺着这条线往下推:
如果 ALA 真能广谱抗衰, RCT 早该证明了, 但至今没有大型寿命 / CVD / 癌症硬终点证据它的真实价值在特定临床适应症, 不是日常保健
Cooperation with thiamin TPP
ALA and thiamin (B1) are the classic example of 'two cofactors on one enzyme' inside mitochondria.The PDH enzyme complex:
PDH is a huge multi-subunit complex (~9 MDa, 60–90 protein units)Three core subunits:E1 (PDH-α/β): uses TPP (thiamin) as cofactor, breaks the C-C bond of pyruvateE2 (dihydrolipoamide acetyltransferase): uses lipoamide (covalently bound ALA) as cofactor, accepts the acetyl groupE3 (dihydrolipoyl dehydrogenase): uses FAD (riboflavin / B2) + nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. (B3) as cofactors, regenerates the oxidized lipoamide
Reaction chain:
```
pyruvate ─→ [E1·TPP] ─→ hydroxyethyl-TPP
↓
[E2·lipoamide] ─→ acetyl-lipoamide ─→ acetyl-CoA (output)
↓ (dihydrolipoamide)
[E3·FAD] ─→ lipoamide (oxidized, recycled) + NADH (energy output)
```
So a single PDH reaction needs 5 cofactors present simultaneously:
TPP (B1) — thiaminlipoamide (ALA) — α-lipoic acidFAD (B2) — riboflavinNAD⁺ (B3) — niacinCoA (B5) — pantothenic acid
This is a quiet convergence of 5 Atlas B-vitamin stories: thiamin/tpp L4, riboflavin/flavins L4, niacin/nad L4, and the pantothenic-acid story all meet at this single enzyme. Any one of them being short slows PDH, jams pyruvate at the end of glycolysis, and piles up lactate.
KGDH (α-ketoglutarate dehydrogenase) has the same cofactor lineup:
At the α-KG → succinyl-CoA step in the tricarboxylic acid (Krebs) cycle: The mitochondrial hub cycle that fully oxidizes fuel and harvests electrons for energy. cycleNeeds TPP + lipoamide + FAD + NAD⁺ + CoA equally
Mechanism takeaway:
'Supplementing ALA boosts energy metabolism' is reasonable when ALA is severely deficient (rare)Modern healthy adults have sufficient endogenous ALA, and this 'cofactor topping-up' hypothesis has almost no RCT support clinicallyIf you really want to support energy metabolism, the priority is: a foundation of food + B1 + B2 + B3 + CoA from diet, vastly outperforming ALA supplementation
This is a concrete sample of how the Atlas uses the 'cofactor cooperation diagram' to explain 'why single supplements often don't work': energy metabolism isn't 'missing X, supplement X' — it's the entire factory running in sync.
Chapter 3
Diabetic neuropathy A-grade
Diabetic neuropathy A-grade
ALA's real A-level clinical evidence is diabetic peripheral neuropathy (DPN) — a prescription drug in Germany / several European countries for 50 years, still a supplement in the US.
The ALADIN series RCTs (1995–2006):
**ALADIN I (Ziegler 1995 *Diabetologia*, n=328)**: IV ALA 600 mg/day × 3 weeks, symptom score (TSS) improved significantly vs placeboALADIN II (Reljanovic 1999, n=65): long-term IV + oral sequential, nerve conduction improvedALADIN III (Ziegler 1999, n=509): IV 600 mg × 3 wk + oral 1800 mg/day × 6 months, sustained improvement**SYDNEY-2 (Ziegler 2006 *Diabetes Care*, n=181)**: oral 600 / 1200 / 1800 mg/day × 5 weeks, dose response, 600 mg/day best value
Ziegler 2006 meta (4 RCTs, n=1,258 pooled):
IV ALA 600 mg/day × 3 wk → TSS (Total Symptom Score) dropped 50% vs placebo 30%Treatment responders (≥ 50% improvement): ~50% in ALA arm vs ~25% in placeboNNT (number needed to treat) ≈ 4, clinically significant
Mechanism (hypothesis):
DPN pathology: hyperglycemia → polyol pathway + protein glycation + oxidative stress → axonal injuryALA → DHLA → clears ROS in nerve tissue + raises GSH + improves nerve microvascular flowDirect antioxidant + improved neural endothelial perfusion
Clinical status (2025):
Germany / Austria / central Europe: ALA (brand Thioctacid) is a prescription drug, approved in 1966, used for DPN for 50+ yearsUS: still OTC supplement, but ADA 2024 guidelines list ALA as 'non-conventional therapy worth considering'China: ALA (thioctic acid injection) is a prescription drug for diabetic neuropathy
What ALA cannot do:
Reverse already-dead neurons — ALA cannot regenerate neuronsSubstitute for glycemic control — glucose control remains the foundation of DPN treatmentPrevent DPN — no primary-prevention evidence
In practice:
Diagnosed DPN + good glycemic control but persistent symptoms: discuss IV ALA 600 mg/day × 3 weeks, or oral 600 mg/day long-term, with endocrinology / neurologyDiabetes + early sensory abnormalities: glycemic control + ADA first-line (pregabalin / duloxetine) is preferred over ALA, but ALA is a reasonable adjunctNon-diabetic neuropathy (chemo / B12 deficiency / alcohol): ALA evidence is weak, not first-line
The ALADIN series RCTs (1995–2006):
**ALADIN I (Ziegler 1995 *Diabetologia*, n=328)**: IV ALA 600 mg/day × 3 weeks, symptom score (TSS) improved significantly vs placeboALADIN II (Reljanovic 1999, n=65): long-term IV + oral sequential, nerve conduction improvedALADIN III (Ziegler 1999, n=509): IV 600 mg × 3 wk + oral 1800 mg/day × 6 months, sustained improvement**SYDNEY-2 (Ziegler 2006 *Diabetes Care*, n=181)**: oral 600 / 1200 / 1800 mg/day × 5 weeks, dose response, 600 mg/day best value
Ziegler 2006 meta (4 RCTs, n=1,258 pooled):
IV ALA 600 mg/day × 3 wk → TSS (Total Symptom Score) dropped 50% vs placebo 30%Treatment responders (≥ 50% improvement): ~50% in ALA arm vs ~25% in placeboNNT (number needed to treat) ≈ 4, clinically significant
Mechanism (hypothesis):
DPN pathology: hyperglycemia → polyol pathway + protein glycation + oxidative stress → axonal injuryALA → DHLA → clears ROS in nerve tissue + raises GSH + improves nerve microvascular flowDirect antioxidant + improved neural endothelial perfusion
Clinical status (2025):
Germany / Austria / central Europe: ALA (brand Thioctacid) is a prescription drug, approved in 1966, used for DPN for 50+ yearsUS: still OTC supplement, but ADA 2024 guidelines list ALA as 'non-conventional therapy worth considering'China: ALA (thioctic acid injection) is a prescription drug for diabetic neuropathy
What ALA cannot do:
Reverse already-dead neurons — ALA cannot regenerate neuronsSubstitute for glycemic control — glucose control remains the foundation of DPN treatmentPrevent DPN — no primary-prevention evidence
In practice:
Diagnosed DPN + good glycemic control but persistent symptoms: discuss IV ALA 600 mg/day × 3 weeks, or oral 600 mg/day long-term, with endocrinology / neurologyDiabetes + early sensory abnormalities: glycemic control + ADA first-line (pregabalin / duloxetine) is preferred over ALA, but ALA is a reasonable adjunctNon-diabetic neuropathy (chemo / B12 deficiency / alcohol): ALA evidence is weak, not first-line
证据链 · ALADIN 系列试验与各国临床现状
在德国和多个欧洲国家, 它已经当处方药用了 50 年 (1966 年获批), 而在美国至今只算补剂。为什么这个适应症证据这么硬? 因为有一整条 RCT 链撑着。上世纪 90 年代到 2006 年的 ALADIN 系列试验 (Ziegler 1995 的 ALADIN I 是开头) 反复验证: 静脉注射 ALA 600 mg/天、连用 3 周, 糖尿病人的神经症状评分明显好转; 后来把这些试验合起来的 meta 分析 (Ziegler 2006) 给出一个好记的数字——大约每治疗 4 个人, 就有 1 个的症状获得实打实的改善 (NNT ≈ 4)。这在临床上算实在的效果。至于每项试验各招了多少人、口服和静脉怎么序贯, 是更细的一层。
临床现状 (截至 2025): 德国、奥地利、中欧一带, ALA (商品名 Thioctacid) 是处方药, 治 DPN 已 50 多年; 美国仍归 OTC 补剂, 但美国糖尿病协会 (ADA) 2024 指南已把它列为可考虑的非传统治疗; 中国也有硫辛酸注射液作为处方药用于糖尿病神经病变。
Why FDA didn't approve
ALA is a prescription drug in Europe for 50 years yet still a supplement in the US — a regulatory-divergence story.The German path:
1966: ALA (brand Thioctacid) was approved by German BfArM for DPN, based on early IV studies + clinical experience1989–2006: the ALADIN series + SYDNEY series RCTs further solidified the evidenceIt remains a routinely used drug in German neurology + diabetology to this day
The US FDA path:
The FDA never formally approved ALA as a drugReasons are complex:No pharma company ever submitted a complete NDA (New Drug Application)ALA's 1955 patent had long expired — no commercial incentiveThe US neuropathy treatment market is dominated by pregabalin (Lyrica, Pfizer) and duloxetine (Cymbalta, Lilly), making it hard for a new generic to break inResult: ALA remains a supplement in the US, and manufacturers cannot claim 'treats diabetic neuropathy'
This tells us:
'Not FDA-approved' ≠ 'ineffective' — regulatory approval is a product of commercial + political + clinical-evidence interplayThe same molecule can be 'drug vs supplement' in different countries, mostly driven by patent / commercial incentive / regulatory preferenceUS off-label prescribing: some physicians do prescribe ALA for diabetic neuropathy, but insurance usually doesn't cover it — patients pay out-of-pocket for supplement-grade ALA
Other similar molecules:
L-carnitine: prescription drug in Europe (heart failure + neuropathy), supplement in the USCoenzyme Q10: prescription drug in Japan (heart failure), supplement in US/EUNAC: FDA prescription drug in US (acetaminophen antidote) + OTC supplement, mostly prescription in Europe5-MTHF (active folate Metafolin): GRAS food ingredient in US, prescription raw material in Europe
In practice:
When evaluating supplements, look at specific evidence grade + indication, not just 'is it FDA-approved''50-year German prescription' + 4 ALADIN RCTs + Ziegler meta is stronger evidence than most US OTC supplementsBut ALA is a DPN drug, not a 'wellness' supplement — the Atlas emphasizes this repeatedly
Chapter 4
Weight loss myth
Weight loss myth
'ALA the fat-loss miracle' is another loud track in ALA marketing — but the actual data is sobering.
Mechanistic basis (hypothesis):
ALA → activates AMP-activated protein kinase: The cell's 'low fuel' sensor — switches on when energy is low to make energy and pause building. → suppresses lipogenesis + promotes fat oxidation (true in animal models)ALA → improves insulin sensitivity, indirectly aiding fat lossALA → suppresses hypothalamic AMPK → reduces appetite (Kim 2004 *Nat Med* mouse study)These mechanisms placed ALA in the 'fat loss + anti-metabolic-syndrome' market narrative
Actual human RCTs (Kucukgoncu 2017 *Obesity Reviews* systematic review + meta):
12 RCTs, n=534 participants (most with metabolic syndrome / diabetes / obesity background)300–1800 mg/day × 8–24 weeksWeighted mean effect: weight −1.27 kg (95% CI −2.29 to −0.25)BMI −0.43 kg/m²Waist circumference: weak signal, not significant
Najafi 2022 meta update:
Similar result: weight −0.65 to −1.5 kg, poor clinical significanceSmall effect + high heterogeneity, with most trials including concurrent diet + exercise
Translated:
'ALA loses 0.65–1.5 kg' is over 8–24 weeks — averaging only 0.1–0.3 kg per monthClinical significance threshold is usually ≥ 5% of starting weight: a 70 kg person needs to lose 3.5 kg — ALA falls far shortCompared with Ozempic (semaglutide): 17–20% weight loss over 68 weeks, 1–2 kg per monthCompared with a plain 500 kcal/day deficit: 0.4–0.5 kg per week, 3–4 kg over 8 weeks
So:
ALA's fat-loss effect is real but negligible in magnitudeIt cannot replace diet + exercise + glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar.-class drugs when meaningful loss is needed'ALA is a weight-loss drug' marketing is a textbook case of a small mechanistic signal being inflated into a clinical hook
Atlas overall: ALA's fat-loss position mirrors its 'anti-aging' position — mechanism plausible, small signal exists, clinical significance weak, marketing far exceeds evidence. If you're prediabetic + insulin-resistant + already doing the diet / exercise basics, ALA is a reasonable marginal trial; if you want ALA to substitute for lifestyle or expect significant weight loss, this road doesn't go there.
Mechanistic basis (hypothesis):
ALA → activates AMP-activated protein kinase: The cell's 'low fuel' sensor — switches on when energy is low to make energy and pause building. → suppresses lipogenesis + promotes fat oxidation (true in animal models)ALA → improves insulin sensitivity, indirectly aiding fat lossALA → suppresses hypothalamic AMPK → reduces appetite (Kim 2004 *Nat Med* mouse study)These mechanisms placed ALA in the 'fat loss + anti-metabolic-syndrome' market narrative
Actual human RCTs (Kucukgoncu 2017 *Obesity Reviews* systematic review + meta):
12 RCTs, n=534 participants (most with metabolic syndrome / diabetes / obesity background)300–1800 mg/day × 8–24 weeksWeighted mean effect: weight −1.27 kg (95% CI −2.29 to −0.25)BMI −0.43 kg/m²Waist circumference: weak signal, not significant
Najafi 2022 meta update:
Similar result: weight −0.65 to −1.5 kg, poor clinical significanceSmall effect + high heterogeneity, with most trials including concurrent diet + exercise
Translated:
'ALA loses 0.65–1.5 kg' is over 8–24 weeks — averaging only 0.1–0.3 kg per monthClinical significance threshold is usually ≥ 5% of starting weight: a 70 kg person needs to lose 3.5 kg — ALA falls far shortCompared with Ozempic (semaglutide): 17–20% weight loss over 68 weeks, 1–2 kg per monthCompared with a plain 500 kcal/day deficit: 0.4–0.5 kg per week, 3–4 kg over 8 weeks
So:
ALA's fat-loss effect is real but negligible in magnitudeIt cannot replace diet + exercise + glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar.-class drugs when meaningful loss is needed'ALA is a weight-loss drug' marketing is a textbook case of a small mechanistic signal being inflated into a clinical hook
Atlas overall: ALA's fat-loss position mirrors its 'anti-aging' position — mechanism plausible, small signal exists, clinical significance weak, marketing far exceeds evidence. If you're prediabetic + insulin-resistant + already doing the diet / exercise basics, ALA is a reasonable marginal trial; if you want ALA to substitute for lifestyle or expect significant weight loss, this road doesn't go there.
人体数据 · 从机制假说到 meta 分析的落差
机制基础 (假说):ALA → 激活 AMP-activated protein kinase: The cell's 'low fuel' sensor — switches on when energy is low to make energy and pause building. → 抑制脂肪合成 + 促进脂肪氧化 (动物模型确实显示)ALA → 改善胰岛素敏感性, 间接减脂ALA → 抑制下丘脑 AMPK → 抑制食欲 (Kim 2004 Nat Med 老鼠研究)这些机制让 ALA 进入减脂 + 抗代谢综合征的市场叙事
实际人体 RCT (Kucukgoncu 2017 Obes Rev 系统综述 + meta):
12 RCT, n=534 参与者 (大多数有代谢综合征、糖尿病、肥胖背景)300-1800 mg/天 × 8-24 周加权平均效应: 体重 −1.27 kg (95% CI −2.29 to −0.25)BMI −0.43 kg/m²腰围: 信号弱, 不显著
Najafi 2022 meta 更新:
类似结果: 体重 −0.65 到 −1.5 kg, 临床显著性差效应小 + 异质性高, 大部分研究有同期减肥饮食 + 锻炼
翻译一下:
ALA 减 0.65-1.5 kg是 8-24 周数据, 平均每月只有 0.1-0.3 kg临床显著标准通常是 ≥ 5% 起始体重: 70 kg 人需要减 3.5 kg, ALA 远远达不到对比司美格鲁肽 2.4 mg (STEP 1, 68 周): 体重下降约 15% (安慰剂 2.4%), 折合每月约 1 kg对比单纯热量赤字 500 kcal/天: 每周 0.4-0.5 kg, 8 周减 3-4 kg
Real position in MetS
ALA's real position in the metabolic syndrome (MetS) + insulin resistance (IR) spectrum.Meaningful signals:
Fasting insulin / HOMA-IR: ALA 300–600 mg/day × 8–24 weeks, HOMA-IR improves 10–20%Fasting glucose: weak signal, not significantHbA1c: weak signal, not significantTriglycerides / LDL: small improvement in some studiesInflammation marker (C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'.): small decrease in some studies
Meaning:
ALA has a 'real but small' effect across the IR spectrum, mostly on early insulin-sensitivity markersCannot replace:Weight loss (first-line for MetS)Metformin (first-line for type 2 diabetes)GLP-1 (newer effective, semaglutide / tirzepatide)Diet (low GI / Mediterranean / DASH)Exercise (resistance + aerobic)
Atlas priority order (MetS / IR intervention):
1. Diet improvement + 5–10% weight loss (A-level hard endpoint, DiRECT trial)
2. Exercise (150 min/week moderate aerobic + 2× resistance, A-level)
3. Metformin (prediabetes → type 2, A-level)
4. glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. class (semaglutide, A-level obesity + DM breakthrough)
5. Berberine (B-level, see berberine story)
6. NAC + vit D + magnesium (B–C level, depending on baseline)
7. ALA 300–600 mg/day (B–C level, marginal trial after #1–5 are dialed in)
8. TMG + creatine + protein (baseline nutrition, not directly targeting MetS)
9. Other (D-level)
In practice:
Metabolic syndrome / IR / prediabetes: #1–3 are core, ALA ranks #7Diagnosed type 2 diabetes + peripheral neuropathy: ALA suddenly becomes A-level (that's the DPN indication)Healthy people who want 'metabolic syndrome protection': no need for ALA — spend the money on diet + exercise + sleep + weight
Bottom line: ALA is a typical supplement-aisle sample of 'clear mechanism + specific clinical niche + extremely broad marketing', in the same tier as NAC / curcumin. Within its precise indications (DPN, part of MetS) it is genuinely effective, but 'anti-aging / fat loss / antioxidant miracle' marketing far exceeds the evidence.
Chapter 5
Decision tree
Decision tree
Do you need to take ALA?
Strongly recommended scenarios (A-level evidence):
1. Diagnosed diabetic peripheral neuropathy (DPN) + persistent symptoms: discuss IV 600 mg/day × 3 weeks, or long-term oral 600 mg/day, with endocrinology / neurology
2. Diabetes + early sensory abnormalities (DPN risk) + glycemic control + medications + still progressing: ALA as adjunct (first-line is still pregabalin / duloxetine)
Worth considering scenarios (B–C evidence):
3. Metabolic syndrome / IR / prediabetes + diet + exercise + weight management already in place + want a marginal add-on: 300–600 mg/day × 8–24 weeks, watching HOMA-IR / weight changes
4. Chemotherapy-induced peripheral neuropathy: evidence weak, but some oncology services will trial it
5. Non-alcoholic fatty liver disease (NAFLD) + metabolic syndrome: small RCT signal, discuss with hepatology / nutrition
Lower priority / not recommended (D-level):
Healthy people taking ALA long-term for 'anti-aging' / 'antioxidant': no hard-endpoint evidence — food + training + sleep have higher ROI'Miracle fat loss': 0.65–1.5 kg over 24 weeks, clinically insignificantPreventing diabetes / DPN: no primary-prevention evidenceNon-diabetic neuropathy (B12 / alcohol / autoimmune): find the cause and treat it; ALA is not a substitute
Dosing protocols:
DPN acute loading: IV 600 mg/day × 3 weeksDPN maintenance: oral 600 mg/day long-termMetabolic syndrome / IR: 300–600 mg/day'Wellness' / general antioxidant: no fixed dose recommended, no supporting evidence
Form choices:
Racemic ALA (50% R + 50% S): cheapest, ~$10–20/month — what the ALADIN series usedR-ALA-Na (sodium salt): more expensive, $40–80/month — better PK, but weak evidence for clinical-endpoint equivalenceR-ALA free acid: unstable, not recommendedCombo metabolic-support multi-ingredient blends: unclear dosing, marketing premium
Safety + side effects:
GI discomfort: 5–10% (at high doses)Rash / allergy: rareInsulin sensitization → hypoglycemia risk: diabetics on glucose-lowering meds must monitor blood glucose and reduce meds as neededThyroid: high-dose ALA may affect T3/T4 — caution in Hashimoto's + Graves' patientsOverdose (> 10 g acute): seizure + death cases reported
Atlas overall: ALA is a typical paradox-molecule in the supplement aisle — a true clinical drug + extensive marketing. Inside the DPN indication it's a real drug; outside the 'anti-aging / weight loss' framing it's marketing. The evaluation point isn't ALA itself — it's that your specific situation determines whether it works for you.
Strongly recommended scenarios (A-level evidence):
1. Diagnosed diabetic peripheral neuropathy (DPN) + persistent symptoms: discuss IV 600 mg/day × 3 weeks, or long-term oral 600 mg/day, with endocrinology / neurology
2. Diabetes + early sensory abnormalities (DPN risk) + glycemic control + medications + still progressing: ALA as adjunct (first-line is still pregabalin / duloxetine)
Worth considering scenarios (B–C evidence):
3. Metabolic syndrome / IR / prediabetes + diet + exercise + weight management already in place + want a marginal add-on: 300–600 mg/day × 8–24 weeks, watching HOMA-IR / weight changes
4. Chemotherapy-induced peripheral neuropathy: evidence weak, but some oncology services will trial it
5. Non-alcoholic fatty liver disease (NAFLD) + metabolic syndrome: small RCT signal, discuss with hepatology / nutrition
Lower priority / not recommended (D-level):
Healthy people taking ALA long-term for 'anti-aging' / 'antioxidant': no hard-endpoint evidence — food + training + sleep have higher ROI'Miracle fat loss': 0.65–1.5 kg over 24 weeks, clinically insignificantPreventing diabetes / DPN: no primary-prevention evidenceNon-diabetic neuropathy (B12 / alcohol / autoimmune): find the cause and treat it; ALA is not a substitute
Dosing protocols:
DPN acute loading: IV 600 mg/day × 3 weeksDPN maintenance: oral 600 mg/day long-termMetabolic syndrome / IR: 300–600 mg/day'Wellness' / general antioxidant: no fixed dose recommended, no supporting evidence
Form choices:
Racemic ALA (50% R + 50% S): cheapest, ~$10–20/month — what the ALADIN series usedR-ALA-Na (sodium salt): more expensive, $40–80/month — better PK, but weak evidence for clinical-endpoint equivalenceR-ALA free acid: unstable, not recommendedCombo metabolic-support multi-ingredient blends: unclear dosing, marketing premium
Safety + side effects:
GI discomfort: 5–10% (at high doses)Rash / allergy: rareInsulin sensitization → hypoglycemia risk: diabetics on glucose-lowering meds must monitor blood glucose and reduce meds as neededThyroid: high-dose ALA may affect T3/T4 — caution in Hashimoto's + Graves' patientsOverdose (> 10 g acute): seizure + death cases reported
Atlas overall: ALA is a typical paradox-molecule in the supplement aisle — a true clinical drug + extensive marketing. Inside the DPN indication it's a real drug; outside the 'anti-aging / weight loss' framing it's marketing. The evaluation point isn't ALA itself — it's that your specific situation determines whether it works for you.
窄适应症 · 剂量协议 · 形态怎么选
可以考虑场景 (B-C 级证据):3. 代谢综合征 / IR / 糖尿病前期 + 已做好饮食 + 运动 + 体重管理 + 想边际加: 300-600 mg/天 × 8-24 周, 观察 HOMA-IR / 体重变化
4. 化疗诱发周围神经病变: 证据弱, 但部分肿瘤科会试
5. 非酒精性脂肪肝 (NAFLD) + 代谢综合征: 小型 RCT 信号, 与肝病科、营养科讨论
剂量协议:
DPN 急性强化: IV 600 mg/天 × 3 周DPN 维持: 口服 600 mg/天长期代谢综合征 / IR: 300-600 mg/天保健/ 一般抗氧化: 不推荐固定剂量, 没有证据支持
形态选择:
Racemic ALA (50% R + 50% S): 最便宜, 约 $10-20/月, ALADIN 系列用的就是这个R-ALA-Na (钠盐): 较贵, $40-80/月, PK 更稳, 但临床终点等价证据弱R-ALA 游离酸: 稳定性差, 不推荐复方代谢支持多分子混合: 剂量不清, 营销溢价
不优先、不推荐场景 (D 级):
健康人抗衰/抗氧化长期吃: 没硬终点证据, 食物 + 训练 + 睡眠性价比更高减肥神药: 0.65-1.5 kg/24 周, 临床显著性差预防糖尿病 / DPN: 没有一级预防证据非糖尿病性神经病变 (B12 / 酒精、自身免疫): 找原因 + 治原因, ALA 不是替代
ALA position in Atlas G4
ALA's position in the Atlas Supplements continent.| Dimension | ALA | NAC | Curcumin | Fish oil | Vit D |
|---|---|---|---|---|---|
| Mechanism clarity | A (cofactor + antioxidant) | A | A | A | A |
| Clinical indication | DPN A-level | paracetamol A | OA mid-high-dose B | EPA/DHA B-A | deficiency A |
| Marginal indication | MetS B / IR C | COPD B / OCD B | anti-inflammation B / depression C | general CVD B-C | general population C |
| Over-marketing | weight loss + anti-aging | anti-COVID | universal anti-inflammatory | heart miracle | prevents everything |
| Real cost | $10–20 (racemic) | $10–15 | $15–30 (poor absorption) | $10–30 | $5–10 |
Shared pattern:
Clear mechanism + specific clinical indication + broad marketingEffective within the true indication, D-level + marketing outside it'Evaluating a supplement = evaluating molecule × person × state' — the Atlas's recurring framework
ALA's position:
Diabetic neuropathy patients: A-level clinical evidence, stronger than the vast majority of supplementsMetabolic syndrome + poor glucose control: B-level adjunct, ranked after diet / exercise / drugsHealthy people wanting anti-aging / fat loss: D-level, not a priority
In the same tier as other 'supplement-grade drugs' with clear indications:
NAC: paracetamol A, COPD B–A, OCD BCurcumin: OA + chronic inflammation B, anti-cancer / anti-aging Domega-3 (EPA + DHA): high triglycerides + selected CVD B–A, general prevention B–CALA: DPN A, MetS B, anti-aging / fat loss D
What unites this group: clear mechanism + strong RCT in a narrow indication + marketing trying to extend it to a broader audience.
Reader's tool: when you see any 'X cures everything' marketing, drop X into this table — the default pattern is 'A in narrow indication, D in broad marketing'.
References · 5
- Shay, K. P., Moreau, R. F., Smith, E. J., Smith, A. R., & Hagen, T. M. (2009). Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochimica et Biophysica Acta, 1790(10), 1149-1160. 10.1016/j.bbagen.2009.07.026
- Packer, L., Witt, E. H., & Tritschler, H. J. (1995). Alpha-lipoic acid as a biological antioxidant. Free Radical Biology and Medicine, 19(2), 227-250. 10.1016/0891-5849(95)00017-R
- Ziegler, D., Nowak, H., Kempler, P., Vargha, P., & Low, P. A. (2004). Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine, 21(2), 114-121. 10.1111/j.1464-5491.2004.01109.x
- Ziegler, D., Hanefeld, M., Ruhnau, K. J., et al. (1995). Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia, 38(12), 1425-1433. 10.1007/BF00400603
- Kucukgoncu, S., Zhou, E., Lucas, K. B., & Tek, C. (2017). Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials. Obesity Reviews, 18(5), 594-601. 10.1111/obr.12528